Navigation Links
Growth factor-promoting angiogenesis expressed in tumor cells and normal neurons

Scientists have discovered that a stem cell factor overexpressed both in brain tumor cells and in neurons following brain injury promotes tumor survival by inducing angiogenesis. The research study, published in the April issue of Cancer Cell, examines the interaction between tumor cells and surrounding tissues and may have substantial significance for design of more effective therapeutics for one of the most lethal types of tumor, malignant gliomas.

Stem cell factor (SCF) is an important growth factor for multiple cell types. Research has shown that SCF is expressed in glioma cells and as a result of various types of brain injury, but its significance is not fully understood. Dr. Howard A. Fine from the National Cancer Institute/National Institute of Neurological Disorders and Stroke at the National Institutes of Health and colleagues designed a study to investigate whether, as a result of tumor-induced brain injury, brain cell-mediated SCF expression contributes to tumor growth by setting up an environment that supports angiogenesis and tumor progression.

The researchers demonstrate that decreased SCF expression in vivo results in decreased angiogenesis and improved survival in mouse glioma models, whereas overexpression of SCF is associated with a worse prognosis and shorter survival in patients with glioblastomas. SCF expression is not directly linked to tumor cell proliferation but instead encourages the growth of blood vessels needed to support the expanding tumor. Importantly, these findings provide definitive evidence that factors promoting tumor progression extend beyond the tumor itself and involve a complex interaction between the cancer cells and the normal cells that are perturbed by expanding tumor.

These results suggest that SCF is a potent glioma-associated angiogenic factor that plays a prominent role in pathological angiogenesis both through direct tumor cell expression of SCF and by normal neurons that are damaged by the gr owing tumor. The researchers point out that the clinical significance of these findings extends beyond identification of SCF as a rational target for gliomas. "Normal neuronal expression of SCF in response to traumatic brain injury also raises the disturbing possibility that standard invasive procedures such as surgical biopsies or partial tumor resections may be inducing a proangiogenic response, or trigger, within the brain," cautions Dr. Fine.


'"/>

Source:Cell Press


Related biology news :

1. Growth in the sea comes down to a struggle for iron
2. Estrogen-like Component of Plastic Stimulates Growth of Certain Prostate Cancer Cells
3. Growth in biomass could put US on road to energy independence
4. Embryonic Stem Cells Treated With Growth Factor Reverse Hemophilia In Mice: UNC Researchers
5. Missing Receptor Molecule Causes Tumor Growth
6. Growth hormone is made in the brain, report scientists
7. New Research Shows Artificial Light at Night Stimulates Breast Cancer Growth in Laboratory Mice
8. Growth factor stimulates rapid extension of key motor neurons in brain
9. Growth hormone to boost athletic performance risks diabetes
10. Growth hormone is not the anti-aging bullet for healthy adults
11. New lead reported in tumor angiogenesis
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/10/2017)... Research and Markets has announced the addition ... and Commercial Aspects" to their offering. ... Biomarkers play an ... for selection of treatment as well for monitoring the results. ... in modern medicine. Biochip/microarray technologies and next generation sequencing are ...
(Date:2/8/2017)... Report Highlights ... The global synthetic-biology market reached nearly $3.9 ... growing at a compound annual growth rate (CAGR) of 24.0% ... global markets for synthetic biology. - Analyses of global market ... of compound annual growth rates (CAGRs) through 2021. - Coverage ...
(Date:2/7/2017)... , Feb. 7, 2017 Zimmer Biomet ... in musculoskeletal healthcare, will present at the LEERINK Partners ... York Palace Hotel on Wednesday, February 15, 2017 at ... webcast of the presentation can be accessed at ... following the conference via Zimmer Biomet,s Investor Relations website ...
Breaking Biology News(10 mins):
(Date:2/23/2017)... 2017 ... share data, unaudited)Three Months Ended December 31,Twelve Months Ended ... $           ... 89026%Aldurazyme Net Product Revenue 3539(10)%9498(4)%Kuvan ... Product Revenue  756025%297303(2)%Vimizim Net Product ...
(Date:2/23/2017)... 23, 2017  MIODx announced today that it ... immunotherapy technologies from the University of California, San ... to monitor a patient for response to immune ... The second license extends the technology with a ... to have an immune-related adverse event (IRAE) from ...
(Date:2/23/2017)... ROCHESTER, Minn. , Feb. 23, 2017 /PRNewswire/ ... a new product line of oncolytic vaccinia viruses ... Genelux Corporation as part of Genelux,s proprietary, vaccinia ... "We are excited to enter into a partnership ... time, selected oncolytic vaccinia viruses for use in ...
(Date:2/23/2017)... ... February 23, 2017 , ... ... annual Inventors Recognition Reception at Purdue Research Park of West Lafayette, ... in recognition of outstanding contributions to, and success with, commercializing discoveries from Purdue ...
Breaking Biology Technology: